Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease

Drug (Brand / Generic)

Austedo™ / deutetrabenazine

Developer

Teva Pharmaceutical Industries

Therapy Class

Vesicular monoamine transporter 2 (VMAT 2) inhibitor

Current Indication

Chorea associated with Huntington’s Disease (HD)

Market Sector

Central nervous system (CNS)

Development Status

Approved in the US
Expand

Go Top